Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | NNMT | P40261 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetone SCHEMBL17732269 | 0.99 | MAPK1 (0.39) | MAPK1NNMTHCAR3KDM4EL3MBTL1 | |
| SCHEMBL30914672 | 0.96 | MAPK1 (0.40) | MAPK1NNMTHCAR3KDM4EL3MBTL1 | |
| SCHEMBL1445644 | 0.96 | MAPK1 (0.40) | MAPK1NNMTHCAR3KDM4EL3MBTL1 | |
| Hydrochloric Acid SCHEMBL310253 | 0.95 | MAPK1 (0.39) | MAPK1NNMTHCAR3KDM4EL3MBTL1 | |
| Hydrochloric Acid SCHEMBL30019344 | 0.95 | MAPK1 (0.39) | MAPK1NNMTHCAR3KDM4EL3MBTL1 | |
| SCHEMBL28248952 | 0.87 | NNMT (0.38) | MAPK1NNMTHCAR3KDM4EL3MBTL1 | |
| SCHEMBL1509187 | 0.83 | MAPK1 (0.41) | MAPK1NNMTHCAR3KDM4EL3MBTL1 | |
| Hydrochloric Acid SCHEMBL5087052 | 0.82 | MAPK1 (0.40) | MAPK1NNMTHCAR3KDM4EL3MBTL1 | |
| SCHEMBL3698235 | 0.82 | MAPK1 (0.38) | MAPK1NNMTHCAR3KDM4EL3MBTL1 | |
| Acetone SCHEMBL993037 | 0.80 | KDM4E (0.35) | MAPK1NNMTHCAR3KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022221706-A1 | METHODS FOR ANTIBODY IDENTIFICATION AND QUANTIFICATION | SEQTECH DIAGNOSTICS LLC (US) | 2022-10-20 | — | — | WO | claimed |
| US-10660972-B2 | Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases | AMICUS THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | claimed |
| EP-2714752-B1 | METHODS FOR COUPLING TARGETING PEPTIDES ONTO RECOMBINANT LYSOSOMAL ENZYMES FOR IMPROVED TREATMENTS OF LYSOSOMAL STORAGE DISEASES | AMICUS THERAPEUTICS INC (US) | 2017-11-22 | — | — | EP | claimed |
| US-20170319710-A1 | METHODS FOR COUPLING TARGETING PEPTIDES ONTO RECOMBINANT LYSOSOMAL ENZYMES FOR IMPROVED TREATMENTS OF LYSOSOMAL STORAGE DISEASES | AMICUS THERAPEUTICS, INC. (US) | 2017-11-09 | — | — | US | claimed |
| US-9545450-B2 | Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases | AMICUS THERAPEUTICS INC. (US) | 2017-01-17 | — | — | US | claimed |
| US-20140302001-A1 | METHODS FOR COUPLING TARGETING PEPTIDES ONTO RECOMBINANT LYSOSOMAL ENZYMES FOR IMPROVED TREATMENTS OF LYSOSOMAL STORAGE DISEASES | CALLIDUS BIOPHARMA, INC. (US) | 2014-10-09 | — | — | US | claimed |
| US-8846875-B2 | Preparation and/or purification of oligonucleotide conjugates | SOLULINK, INC. (US) | 2014-09-30 | — | — | US | claimed |
| WO-2014082080-A2 | METHODS FOR COUPLING TARGETING PEPTIDES ONTO RECOMBINANT LYSOSOMAL ENZYMES FOR IMPROVED TREATMENTS OF LYSOSOMAL STORAGE DISEASES | CALLIDUS BIOPHARMA, INC. (US) | 2014-05-30 | — | — | WO | claimed |
| WO-2012166653-A2 | METHODS FOR COUPLING TARGETING PEPTIDES ONTO RECOMBINANT LYSOSOMAL ENZYMES FOR IMPROVED TREATMENTS OF LYSOSOMAL STORAGE DISEASES | CALLIDUS BIOPHARMA, INC. (US) | 2012-12-06 | — | — | WO | claimed |
| US-20060153839-A1 | Production of bispecific molecules using polyethylene glycol linkers | ELUSYS THERAPEUTICS, INC. (US) | 2006-07-13 | — | — | US | claimed |
| EP-1539811-A4 | PRODUCTION OF BISPECIFIC MOLECULES USING POLYETHYLENE GLYCOL LINKERS | ELUSYS THERAPEUTICS INC (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1539811-A2 | PRODUCTION OF BISPECIFIC MOLECULES USING POLYETHYLENE GLYCOL LINKERS | Elusys Therapeutics, Inc. (US) | 2005-06-15 | — | — | EP | claimed |
| WO-2004024889-A2 | PRODUCTION OF BISPECIFIC MOLECULES USING POLYETHYLENE GLYCOL LINKERS | ELUSYS THERAPEUTICS, INC. (US) | 2004-03-25 | — | — | WO | claimed |
| US-12019078-B2 | Macromolecule analysis employing nucleic acid encoding | Encodia, Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12019077-B2 | Macromolecule analysis employing nucleic acid encoding | Encodia, Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240125792-A1 | KITS FOR ANALYSIS USING NUCLEIC ACID ENCODING AND/OR LABEL | DF PEPTIDE ACQUISITION LLC | 2024-04-18 | — | — | US | disclosed |
| US-20020146504-A1 | Ternary biomolecule/polymer/surface-based immobilization systems | AUDAX PRIVATE DEBT LLC, AS AGENT | 2002-10-10 | — | — | US | disclosed |
| WO-2002057422-A2 | TERNARY BIOMOLECULE/POLYMER/SURFACE-BASED IMMOBILIZATION SYSTEMS | SCHWARTZ DAVID A (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002010432-A2 | TRIPHOSPHATE OLIGONUCLEOTIDE MODIFICATION REAGENTS AND USES THEREOF | SCHWARTZ DAVID A (US) | 2002-02-07 | — | — | WO | disclosed |
| WO-2001070685-A2 | HYDRAZINE-BASED AND CARBONYL-BASED BIFUNCTIONAL CROSSLINKING REAGENTS | SOLULINK, INCORPORATED (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020146504-A1 | Ternary biomolecule/polymer/surface-based immobilization systems | EPCAM, DNPEP, ANPEP | MAPK1 3974/4885NNMT 1358/4885HCAR3 467/4885 |
| US-20060153839-A1 | Production of bispecific molecules using polyethylene glycol linkers | TNFSF11, TNFSF10, CLTA | MAPK1 2259/4885NNMT 4318/4885HCAR3 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.